

Mylan Pharmaceuticals Inc., Petitioner

v.

Nissan Chemical Industries Ltd.  
Patent Owner

U.S. Patent No. 5,856,336 to Fujikawa *et al.*  
Issue Date: January 5, 1999  
Title: Quinoline Type Mevalonolactones

*Inter Partes* Review No.: IPR2015-01069

**DECLARATION OF AMY D. BRODY IN SUPPORT OF  
MYLAN PHARMACEUTICALS INC.'S MOTION  
FOR *PRO HAC VICE* ADMISSION (EXHIBIT 1043)**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Hubbard Street, Suite 500, Chicago, Illinois 60654.

2. I am an experienced litigator, with nearly fifteen (15) years of litigation experience, including over ten (10) years of patent litigation experience. I have represented clients in numerous patent infringement actions in various technical areas relating to the chemical and pharmaceutical arts.

3. I am a member in good standing of the Bars of the State of Illinois (2000) and the District of Columbia (2002). I am also admitted to practice before the following courts: United States Court of Appeals for the Federal Circuit (2004); United States Court of Appeals for the District of Columbia (2004); and the United States District Court for the Northern District of Illinois (2000).

4. I have never been suspended or disbarred from practice before any court or administrative body.

5. I have never been denied admission to practice before any court or administrative body.


6. I have never been subject to sanctions or contempt citations imposed by any court or administrative body.

8. I agree to be subject to the United States Patent and Trademark Office Rules of Professional Responsibility set forth in parts 10 and 11 of 37 C.F.R. and to disciplinary jurisdiction under 37 C.F.R. § 11.19(a). I have not appeared *pro hac vice* in any proceedings before the United States Patent and Trademark Office in the past three (3) years.

9. I have an established familiarity with the subject matter at issue in the current proceeding, IPR2015-01069. Specifically, I have reviewed the challenged patent, the Petition, the accompanying exhibits and the Preliminary Response (with accompanying exhibits) to the Petition. I represent Mylan Pharmaceuticals Inc. (“Mylan”) in the underlying district court litigation, which involves claims of non-infringement and invalidity of the patent-at-issue in this *Inter Partes* Review (“IPR”). *See Kowa Company, Ltd. v. Mylan, Inc.*, Civil Action No. 1:14-cv-02647-PAC (S.D.N.Y. filed Apr. 14, 2014). I am involved in all aspects of that pending district court litigation. As a result of my representation of Mylan, I have acquired substantial understanding of the technology relevant to this IPR.

Dated: August 19, 2015

Respectfully submitted,



---

Amy D. Brody

([abrody@rmmslegal.com](mailto:abrody@rmmslegal.com))

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

6 West Hubbard Street, Suite 500

Chicago, Illinois 60654

(312) 222-6344 (telephone)

(312) 222-6345 (facsimile)